entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:33:39 - browse：736

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

WSS

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Tuskegee Airman Raymond Cassagnol dies at 102

ADA: All diabetes patients should be screened for liver condition

Trump Jan. 6 attorney John Lauro is ex

UnitedHealth wins $3.3 billion takeover of Amedisys

hotspot

entertainment

The need-to-know this morning

Is it time to worry about Moderna?

leisure time

What does generative AI mean for health care? We asked experts

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Moonlake's readout produced a cash windfall. Risks remain

Eating disorder hotline's move to chatbot carried cost for volunteers

BioMarin wins approval for gene therapy to treat hemophilia A

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Moderna hits safety problems in bold bid to reinvent medicine

knowledge

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Ukrainian soldiers say they owe lives to US

Boeing's 1st astronaut flight bumped into next year, more repairs needed

GOP inquiry over gain

ADA: All diabetes patients should be screened for liver condition

entertainment

knowledge

explore

hotspot